Incremental associations of pharmacological components in heart failure with mildly reduced or preserved ejection fraction: a systematic review and component network meta-analysis.
Researchers
Mohammad Ali Omrani, Bala Swetha Baskaran, Atefeh Jafari, Lujain Ez Eddin, Fatemeh Ahmadi, Manik Chhabra, Mê-Linh Lê, Sheikh Abdullah, Kristin Clemens, Flory T Muanda
Abstract
We conducted a component network meta-analysis (CNMA) of phase 3/4 randomized trials to evaluate incremental effects of pharmacological therapies in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF; LVEF > 40%). MEDLINE, Embase, and Cochrane were searched through 1 August 2025 (updated 30 March 2026). We performed an additive CNMA evaluating cardiovascular death or first heart failure hospitalization (HFH) and assessed certainty of evidence. Twenty-four trials and five secondary reports were included. The primary network was sparse (10 trials, 12 regimens), constraining interaction detection and component stability. Incretin-based interventions (pooling semaglutide and tirzepatide, iHR 0.69, 95% CI 0.53-0.91), SGLT-2 inhibitors (0.80, 0.74-0.88), ARNis (0.82, 0.68-0.99), and MRAs (0.89, 0.81-0.98) showed significant component associations, driven principally by fewer HFHs. No drug class significantly reduced mortality. SGLT-2 inhibitors and MRAs remained significant across sensitivity analyses except LVEF ≥ 50%, with SGLT-2 inhibitors most precise. ARNi benefits lost significance under stricter background therapy thresholds (>60%) and contemporary trial restrictions. Evidence for incretins was low-certainty and sensitive to trial selection. SGLT-2 inhibitors and MRAs provide the most robust incremental benefit, while evidence for other drug classes remains context-dependent. These findings should guide research priorities rather than define combination regimens. http://www.crd.york.ac.uk PROSPEROidentifier is CRD420251107058.Source: PubMed (PMID: 43065287)View Original on PubMed